Literature DB >> 30319901

Cross-section and feasibility study on the non-invasive evaluation of muscle hemodynamic responses in Duchenne muscular dystrophy by using a near-infrared diffuse optical technique.

Wen-Chin Weng1,2,3, Jung-Chih Chen4, Chia-Yen Lee5, Chia-Wei Lin6, Wang-Tso Lee1,2,3, Jeng-Yi Shieh7, Chia-Chen Wang4, Ching-Cheng Chuang4.   

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked debilitating muscular disease that may decrease nitric oxide (NO) production and lead to functional muscular ischemia. Currently, the 6-minute walk test (6-MWT) and the North Star Ambulatory Assessment (NSAA) are the primary outcome measures in clinical trials, but they are severely limited by the subjective consciousness and mood of patients, and can only be used in older and ambulatory boys. This study proposed using functional near-infrared spectroscopy (fNIRS) to evaluate the dynamic changes in muscle hemodynamic responses (gastrocnemius and forearm muscle) during a 6-MWT and a venous occlusion test (VOT), respectively. Muscle oxygenation of the forearm was evaluated non-invasively before, during and after VOT in all participants (included 30 DMD patients and 30 age-matched healthy controls), while dynamic muscle oxygenation of gastrocnemius muscle during 6-MWT was determined in ambulatory participants (n = 18) and healthy controls (n = 30). The results reveal that impaired muscle oxygenation was observed during 6-MWT in DMD patients that may explain why the DMD patients walked shorter distances than healthy controls. Moreover, the results of VOT implied that worsening muscle function was associated with a lower supply of muscle oxygenation and may provide useful information on the relationship between muscular oxygen consumption and supply for the clinical diagnosis of DMD. Therefore, the method of fNIRS with VOT possesses great potential in future evaluations of DMD patients that implies a good feasibility for clinical application such as for monitoring disease severity of DMD.

Entities:  

Keywords:  (170.0170) Medical optics and biotechnology; (170.1610) Clinical applications; (170.2655) Functional monitoring and imaging; (170.4580) Optical diagnostics for medicine

Year:  2018        PMID: 30319901      PMCID: PMC6179388          DOI: 10.1364/BOE.9.004767

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  51 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 2.  Skeletal muscle BOLD MRI: from underlying physiological concepts to its usefulness in clinical conditions.

Authors:  Bjoern Jacobi; Georg Bongartz; Sasan Partovi; Anja-Carina Schulte; Markus Aschwanden; Alan B Lumsden; Mark G Davies; Matthias Loebe; Georg P Noon; Sasan Karimi; John K Lyo; Daniel Staub; Rolf W Huegli; Deniz Bilecen
Journal:  J Magn Reson Imaging       Date:  2012-06       Impact factor: 4.813

Review 3.  Function and genetics of dystrophin and dystrophin-related proteins in muscle.

Authors:  Derek J Blake; Andrew Weir; Sarah E Newey; Kay E Davies
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

Review 4.  Near-infrared spectroscopy for monitoring muscle oxygenation.

Authors:  R Boushel; C A Piantadosi
Journal:  Acta Physiol Scand       Date:  2000-04

5.  The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.

Authors:  Craig M McDonald; Erik K Henricson; Jay J Han; R Ted Abresch; Alina Nicorici; Gary L Elfring; Leone Atkinson; Allen Reha; Samit Hirawat; Langdon L Miller
Journal:  Muscle Nerve       Date:  2010-04       Impact factor: 3.217

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

7.  Noninvasive measurement of forearm blood flow and oxygen consumption by near-infrared spectroscopy.

Authors:  R A De Blasi; M Ferrari; A Natali; G Conti; A Mega; A Gasparetto
Journal:  J Appl Physiol (1985)       Date:  1994-03

8.  Vascular-targeted therapies for Duchenne muscular dystrophy.

Authors:  James P Ennen; Mayank Verma; Atsushi Asakura
Journal:  Skelet Muscle       Date:  2013-04-23       Impact factor: 4.912

9.  The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Julaine M Florence; Michelle Eagle; Eduard Gappmaier; Allan M Glanzman; Robert Spiegel; Jay Barth; Gary Elfring; Allen Reha; Stuart Peltz
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

10.  A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.

Authors:  Ronald G Victor; H Lee Sweeney; Richard Finkel; Craig M McDonald; Barry Byrne; Michelle Eagle; Nathalie Goemans; Krista Vandenborne; Alberto L Dubrovsky; Haluk Topaloglu; M Carrie Miceli; Pat Furlong; John Landry; Robert Elashoff; David Cox
Journal:  Neurology       Date:  2017-09-29       Impact factor: 9.910

View more
  1 in total

1.  Decrease in Cerebral Oxygen Saturation During the 6-Minute Walk Test in Pediatric Pulmonary Arterial Hypertension.

Authors:  Leman Tekin Orgun; Zeynep Öztürk; Fatma Hayvacı Canbeyli; Dilek Yapar; Kıvılcım Gücüyener; Serdar Kula
Journal:  Pediatr Cardiol       Date:  2019-07-31       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.